Nephrology

The USPSTF is rumored to have moved screening for chronic kidney disease to a preventive service it is actively considering and the NFK says, "It's time."

Kosiborod, a cardiologist, and Skolnik, a family practitioner, agree no single specialty owns that prescription and that "it takes a village to care for a patient."

Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.

Initiation of second-line type 2 diabetes treatment is lagging while A1c at the time it is introduced is climbing. The author of a new study highlights his findings on clinical inertia.

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.

The phase 3 EMPA-KIDNEY clinical trial had just met prespecified criteria for positive efficacy when the study's Independent Data Monitoring Committee recommended the early halt.

Type 2 diabetes patients-and their PCPs-may have trouble moving to basal + mealtime insulin from basal insulin alone. Endocrinologist Brian Levy, MD, offers insights.

Use of continuous glucose monitoring to assess time in target glucose range in T2D patients was evaluated in a systematic literature review covering ~14 000 participants.

The ADA's annual update to its comprehensive evidence-based standards includes new guidance on diabetes screening, first-line therapies, and comorbid NAFLD/NASH.

Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.

The Guideline Toplines slide-show feature offers busy primary care physicians at-a-glance summaries of new and updated clinical guidelines across therapeutic areas.

Finerenone was associated with a 20% lower risk of end-stage kidney disease among patients with T2D and CKD, according to authors of the FIDELITY analysis.

Hypertension, chronic kidney disease, and NAFLD/NASH are frequently first diagnosed in primary care. Try these 10 questions on diagnosis and treatment of all 3.

Finerenone, in patients with mild-to-moderate renal disease and T2D, reduced CV event risk by 13% and risk for a composite renal event by 23%, study authors reported at ESC 2021.

The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.

The first nonsteroidal mineralocorticoid receptor antagonist to be approved for adults with T2D-associated CKD fills a significant treatment void for millions of patients.

The SGLT-2 inhibitor class, originally approved as antihyperglycemic agents for T2D, has proven "pluripotent," adding indications for related conditions. Test your knowledge of a few basic facts.

Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.

ADA 2021: The investigational exendin-4-based GLP-1 RA was associated with a 27% decrease in risk for a CV event and a 32% reduction in risk for CKD progression.